Contineum Therapeutics CTNM Ratios (2023-2026)

NASDAQ CTNM
$16.59 -0.98 (-5.55%)
As of: Sep 4, 2026 · 3:14 PM EDT
Reported Financials

Contineum Therapeutics Quarterly Ratios

Periods 12 quarters
Latest Jun 2026

Contineum Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 12 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Mar2023 Jun2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin 84.60%
EBIT Margin 77.87%
EBITDA Margin 77.87%
Operating Margin 77.87%
Net Margin 83.14%
FCF Margin 81.29%
Efficiency
Assets AverageAssets Avg. 126.97M172.46M218.69M214.44M205.56M190.58M186.87M233.74M269.00M255.86M
Asset Utilization RatioAsset Util. 0.29
Leverage & Solvency
Interest Coverage RatioInterest Cover -55.60335.66
Times Interest Earned -55.60335.66
Valuation
Price to EarningsP/E -50.28-47.97-66.68-11.29-6.41-26.81-28.24-28.00-40.71
Price to BookP/B 2.082.341.910.980.601.901.631.952.56
Enterprise Value 234.33M278.56M174.01M-10.14M-72.68M160.49M163.67M241.32M377.55M
EV to EBIT -21.41-21.47-10.210.564.06-10.75-9.56-14.28-21.66
EV to EBITDA -21.41-21.47-10.210.564.06-10.75-9.56-14.28-21.66
Market Capitalization 452.99M492.47M378.77M180.57M102.81M342.89M426.57M487.65M614.10M
Price to FCFP/FCF -61.08-79.84-37.13-12.49-6.55-27.89-32.60-29.42-53.37
EV to FCF -31.60-45.16-17.060.704.63-13.05-12.51-14.56-32.81
EV to CFO -27.57-45.16-17.060.704.64-13.16-12.55-14.84-32.83
Return Ratios
Return on Sales [ROS]ROS 77.87%-77.24%
Return on Capital Employed [ROCE]ROCE 9.33%-22.89%-20.44%-24.89%-30.05%-36.01%-37.67%-30.38%-25.48%-26.62%
Return on Assets [ROA]ROA 11.58%-20.81%-18.24%-15.56%-20.90%-26.15%-28.12%-26.51%-22.81%-23.68%